Navigation Links
Experimental Drug Raises Good Cholesterol Levels in Early Trial
Date:11/17/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Nov. 17 (HealthDay News) -- An experimental drug that raises HDL, or "good," cholesterol seems to have passed an initial hurdle by proving safe in preliminary trials.

Although the trial was primarily designed to look at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual meeting in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and cut LDL, HDL's evil twin, almost in half.

"We saw very encouraging reductions in clinical events," said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.

A big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.

Other experts are intrigued by the findings, but note that the research is still in very early stages.

"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery," said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.

Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very preliminary but it's important because the last drug out of the barrel of this type was not a success. This looks like a better drug, but it's not definitive by any means. Don't take this to the bank."

LaRosa was referring to torcetrapib, which, like anacetrapib, belongs to the class of drugs known as cholesterol ester transfer protein (CETP) inhibitors.

A large trial on torcetrapib was killed after investigators found an increased risk of death and other cardiovascular outcomes.

"I would be more excited [about anacetrapib] if I hadn't seen what happened to its cousin torcetrapib," Weintraub said. "Torcetrapib raised HDL astoundingly but that was entirely neutralized by the increase in cardiovascular events."

In the new trial, anacetrapib actually showed a tendency toward fewer cardiovascular problems and fewer angioplasty or bypass procedures, although the study only lasted 18 months.

It also didn't result in the blood pressure increases that helped doom torcetrapib.

To assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.

At the end of six months, LDL cholesterol was cut 81 milligrams per deciliter (mg/dl) of blood to 45 mg/dl, a reduction of about 40 percent. In the placebo group, LDL levels only declined from 82 mg/dl to 77 mg/dl.

Meanwhile, HDL levels increased from 41 mg/dl of blood to 101 mg/dl in the treatment arm, versus a small jump from 40 mg/dl to 46 mg/dl in the placebo group.

"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events," said Brigham and Women's Cannon. "That will be the subject of a larger study."

Such a study is in the works, he added.

Dr. Neil Coplan, director of clinical cardiology at Lenox Hill Hospital in New York City, stressed that this was a "safety trial, not a trial which is saying in any way that people should take these medications nor are the drugs approved."

Still, he added, "the trial demonstrated safety and it demonstrated a tremendous effect on altering the lipid profile in a good direction. It's very promising but, as the authors note themselves, it's a first step."

Experts are still divided as to whether raising HDL levels will actually result in any meaningful improvements in clinical outcomes.

"Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising," said Weintraub, who added that results should be available relatively soon from other trials exploring the issue. "The fact that LDL was also reduced also makes it promising."

"We've never been able to satisfactorily demonstrate that raising HDL actually changes risk," added LaRosa.

The only drug currently available to raise HDL is nyacin.

More information

The American Heart Association has more on understanding your cholesterol levels.

SOURCES: Christopher P. Cannon, M.D., cardiologist, Brigham and Women's Hospital, Boston; Howard Weintraub, M.D., clinical director, Center for the Prevention of Cardiovascular Disease, NYU Langone Medical Center, New York City; John C. LaRosa, M.D., president, State University of New York (SUNY) Downstate Medical Center, New York City; Neil Coplan, M.D., director, clinical cardiology, Lenox Hill Hospital, New York City; Nov. 18, 2010, New England Journal of Medicine; Nov. 17, 2010, presentation, American Heart Association annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UT Southwestern researchers create experimental vaccine against Alzheimers
2. Experimental Drug Aids Kids With Nervous System Tumor
3. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
4. Experimental Leukemia Drug Proves a Slam Dunk
5. Experimental Drug Shows Promise for Bone Marrow Disorder
6. Experimental TB Test Called Fast and Accurate
7. Experimental treatments for cocaine addiction may prevent relapse
8. Experimental obesity drug avoids brain effects that troubled predecessors
9. Experimental nonsteroidal treatment of asthma shows promise
10. Experimental targeted therapy shows early promise against medulloblastomas
11. Experimental Vaccine Shields Monkeys Against Ebola
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Raises Good Cholesterol Levels in Early Trial
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: